Laird Norton Wetherby Wealth Management’s NovoCure NVCR Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,907	Closed	-$221K	–	943
2022 Q3	$221K	Sell	2,907 -36	-1%	-$2.81K	0.02%	777
2022 Q2	$205K	Buy	2,943 +246	+9%	+$18.5K	0.01%	807
2022 Q1	$223K	Sell	2,697 -190	-7%	-$14K	0.01%	823
2021 Q4	$217K	Buy	2,887 +172	+6%	+$17.3K	0.01%	835
2021 Q3	$315K	Sell	2,715 -103	-4%	-$15.6K	0.02%	693
2021 Q2	$625K	Buy	2,818 +366	+15%	+$71.2K	0.04%	435
2021 Q1	$324K	Sell	2,452 -194	-7%	-$30.7K	0.02%	581
2020 Q4	$458K	Buy	2,646 +388	+17%	+$53.1K	0.03%	488
2020 Q3	$251K	Buy	+2,258	New	+$181K	0.02%	574

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's NVCR Position: Q4 2022 in Review

Laird Norton Wetherby Wealth Management sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 2,907 shares — an estimated $221K sold.

Laird Norton Wetherby Wealth Management first reported a position in NVCR in Q3 2020 and held it in 9 quarters. The position peaked at $625K in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

Laird Norton Wetherby Wealth Management reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 2,907 NovoCure shares in Q4 2022, an estimated $221K.
Laird Norton Wetherby Wealth Management first reported a position in NovoCure in Q3 2020 and held it in 9 quarters.
Laird Norton Wetherby Wealth Management's NovoCure position peaked at $625K in Q2 2021.
304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.